Furthermore, we suggest that inhibition of extracellular GzmB activity may be an adjunctive therapy to support existing anti-VEGF treatments, and to potentially treat AMD patients who are non-responsive or whose disease has become resistant to anti-VEGFs drugs. This evidence concerns the gene VEGFA and age-related macular degeneration.